The value of urotensin II in patients with left-sided rheumatic valvular regurgitation

Abstract

AimsRheumatic valve diseases are most common etiological valve diseases in developing countries. Urotensin II is cardiovascular autacoid/hormone and may be associated with patients of heart valve diseases. The present study was to measure plasma urotensin II concentrations in patients with left-sided rheumatic valve diseases such as mitral regurgitation (MR) and aortic regurgitation (AR), and to examine its correlation with severity of valve impairment, function (New York Heart association, NYHA) class and pulmonary artery pressure (PAP).Methods and resultsSixty patients with moderate to severe rheumatic left-sided valve regurgitation and 20 healthy controls were selected after performing the echocardiography. Plasma urotensin II level was measured in all subjects. The patients with MR and AR were significantly increased of left ventricular end diastolic dimension (LVEDD), left ventricular end systolic dimension (LVESD), left atrial diameter, PAP, but decreased of EF% versus the controls. Urotensin II level was highly significant in patients with MR (1.83 ± 0.92 ng/ml, P < 0.001) and AR (0.79 ± 0.3 ng/ml, P < 0.05) versus the controls (0.48 ± 0.13 ng/ml). Also, there was significant correlation between Urotensin II level and LVEDD (MR, r = 0.318, P = 0.03; AR, r = 0.805, P < 0.001), LVESD (MR, r = −0.271, P = 0.115; AR, r = 0.614, P = 0.001), and PAP (MR, r = 0.706, P < 0.001; AR, r = 0.129, P = 0.538).ConclusionUrotensin II was elevated in patients with rheumatic left-sided valvular regurgitation, and positively correlated with increased LVEDD (in both MR and AR), LVESD (only AR) and pulmonary artery pressure (only MR). Therefore, urotensin II level may be used as diagnostic biomarker in patients with rheumatic valvular diseases for assessment of the severity in parallel with echocardiography.

Identifying Circulating Urotensin II and Urotensin II-Related Peptide-Generating Enzymes in the Human Plasma Fraction Cohn IV-4

“…The latter seems to be more likely, as several groups reported that high levels of UII negatively correlate with the outcome of patients with myocardial infarcts. ,, More recently, in patients with hypertrophic cardiomyopathy significantly higher serum levels of UII were detected . Also, in patients with rheumatic valve disease, plasma levels of UII were elevated . In both cases, UII levels might function as a diagnostic tool. , The UTR-antagonist urantide was shown to protect atherosclerosis. , It improves the cardiac function, modulates cytokine response, and increases survival in a murine model of endotoxic shock .…”

“…27 plasma levels of UII were elevated. 28 In both cases, UII levels might function as a diagnostic tool. 27,28 The UTR-antagonist urantide was shown to protect atherosclerosis.…”

“…28 In both cases, UII levels might function as a diagnostic tool. 27,28 The UTR-antagonist urantide was shown to protect atherosclerosis. 29,30 It improves the cardiac function, modulates cytokine response, and increases survival in a murine model of endotoxic shock.…”

“…Also, in patients with rheumatic valve disease, plasma levels of UII were elevated . In both cases, UII levels might function as a diagnostic tool. , The UTR-antagonist urantide was shown to protect atherosclerosis. , It improves the cardiac function, modulates cytokine response, and increases survival in a murine model of endotoxic shock . Also, urantide improved an atherosclerosis-related kidney injury via the JAK2/STAT3 pathway in rats and alleviated myocardial damage in atherosclerotic rats by regulation of the MAPK pathway …”

Urotensin II: an inflammatory cytokine

“…In the heart, UII can enhance the cardiotoxic oxidative stress response (Rahimi et al 2018) and increase PKA activity to induce the hypertrophy of neonatal cardiac myocytes (Xu et al 2017). It also plays an important role in the development of adult hypertrophic cardiomyopathy (Jumaah et al 2018) and rheumatic valvular disease (Elmadbouh et al 2017). In fact, the biofunctions of UII are not only confined to the cardiovascular system, but UII also has extensive and profound effects on many tissues and cells in the body.…”